A Safety, Efficacy and Tolerability Study of SEP-225289

NCT00584974 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

523

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: SEP-225289
DRUG: SEP-225289
DRUG: Venlafaxine
DRUG: placebo

Sponsor

Sumitomo Pharma America, Inc.